Clinical Trial Update: High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose gemcitabine, busulfan, and melphalan with hematopoietic-cell support in poor-risk myeloma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BUSULFAN (Busulfan)
• Gemcitabine (Gemcitabine)
• Melphalan (Melphalan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-05-05